Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease

Documenti analoghi

• Benefits of lowering cholesterol in chronic kidney disease Reply
  di: Baigent, C, et al.
  Pubblicazione: (2011)
• Estimated glomerular filtration rate and the risk of major vascular events and all-cause mortality: a meta-analysis.
  di: Mafham, M, et al.
  Pubblicazione: (2011)
• Use of causal diagrams to inform the analysis and interpretation of observational studies: An example from the Study of Heart and Renal Protection (SHARP)
  di: Staplin, N, et al.
  Pubblicazione: (2016)
• Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
  di: Mihaylova, B, et al.
  Pubblicazione: (2019)
• Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men.
  di: Emberson, JR, et al.
  Pubblicazione: (2010)